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changes in treatments’ effect on weight and HbA1c, and in utility values related to 
weight changes. Dapagliflozin’s higher health benefits and cost savings are mainly 
explained by its greater beneficial effect on weight, leading to higher QALYs and less 
drug costs for dapagliflozin patients. The lower treatment costs are related to the 
insulin treatment costs (i.e. subsequent line regimens) due to the lower weight of 
dapagliflozin patients observed over time, which eventually leads to lesser insulin 
dosage. ConClusions: Dapagliflozin is a cost-saving strategy with higher health 
benefits compared to DPP4, added to metformin, for Turkish T2DM patients inad-
equately controlled on metformin mono-therapy.
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objeCtives: Economic modelling in type 1 diabetes mellitus (T1DM) is complex and 
continuously evolving. The aim of this systematic review was to assess methodologi-
cal capabilities of T1DM models. Methods: A systematic search was undertaken 
in MEDLINE®, Embase®, and the Cochrane library to identify economic evaluation 
models in T1DM (English language until November 2014). The websites of HTA bod-
ies in England, Canada, Australia, France, Germany, Scotland and Spain were also 
screened. Study inclusion was based on a pre-specified protocol and carried out by a 
team of reviewers and information scientists independently, and data was extracted 
focusing on methodological capabilities. Results: 74 publications describing 13 
unique models were identified. Most models employed a Markov structure, and 
all included microvascular complications while five included both microvascu-
lar and macrovascular complications. Patient-level (microsimulation) and cohort 
approaches were equally common. While naturally varying across models, the risk 
equations that simulated event rates were generally based on a small set of studies 
which are now more than 20 years old. Treatment-effects were simulated in several 
ways; the more comprehensive models used surrogate risk factors (mostly HbA1c) to 
modify the risk of complications, but other approaches included directly modifying 
complication rates, quality-of-life, and/or resource use. The most common adverse 
events included in the models were hypoglycemia and ketoacidosis. Although the 
details provided varied, five models explicitly reported probabilistic sensitivity 
analysis capabilities. ConClusions: There was considerable heterogeneity in 
the models, likely driven by varying intended uses. The sub-set of models clearly 
intended for cost-effectiveness applications used more sophisticated approaches to 
capturing uncertainty and were among the most comprehensive, tending to include 
both micro- and macrovascular outcomes and common treatment-related adverse 
events. These models are likely to provide the most useful set of model capabilities 
despite relying on aging risk equations.
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objeCtives: To estimate the cost-effectiveness of using CANA versus DAPA or EMPA, 
three agents that inhibit sodium glucose co-transporter 2 (SGLT2), as monotherapy 
from the UK NHS perspective. Methods: The validated ECHO-T2DM model was 
used to estimate 40-year outcomes and costs associated with using CANA 100 or 
300mg versus DAPA 10mg or EMPA 25mg. Data from a 26-week network meta-analysis 
(NMA) performed to support a NICE multiple technology assessment were used to 
populate the model with treatment effects for HbA1c, blood pressure, weight and rates 
of hypoglycaemic events (hypoglycaemia data for EMPA were not possible to report 
from the NMA). Changes in lipids and rates of adverse events (AEs) associated with 
SGLT2 inhibition (i.e., urinary tract infections, genital mycotic infections) were sourced 
from a CANA monotherapy trial; values for DAPA and EMPA were assumed the same 
as CANA 100mg (as was the hypoglycaemia rate for EMPA). Sensitivity analyses were 
also performed. Results: In the base case, CANA 100mg dominated DAPA and EMPA 
with quality-adjusted life-year (QALY) gains of 0.033 and 0.015 and lower total costs of 
£69 and £3. CANA 300mg versus DAPA provided an estimated QALY gain of 0.075 and 
increased cost of £709, resulting in an incremental cost-effectiveness ratio (ICER) of 
£9,429. Versus EMPA, the ICER was slightly higher (£13,491), but still below the gener-
ally accepted threshold in the UK, with a QALY gain of 0.056 and an increased cost 
of £761. Sensitivity analyses supported these base case findings. ConClusions: 
Through an insulin-independent mechanism of action, agents that inhibit SGLT2 
improve glucose levels, blood pressure, and weight, with a low inherent risk of hypo-
glycaemia. These results suggest that both CANA 100 and 300mg are likely to be 
cost-effective monotherapy options versus DAPA and EMPA in the UK.
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objeCtives: Gestational diabetes mellitus (GDM) is associated with elevated risk 
of severe perinatal complications and type 2 diabetes (T2DM). Screening and inter-
vention is recognized as an effective way to reduce these risks. The prevalence rate 
of GDM was as high as 17.5% in China, which caused a huge economic burden. 
GDM screening and intervention was reported in many hospitals in China, however, 
lacking evaluation from an economic perspective up to now. The objective was 
to estimate the long-term cost-effectiveness associated with GDM screening in 
the urban Chinese setting to provide economic evidence for clinical practice and 
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objeCtives: To evaluate the long-term cost-effectiveness of dapagliflozin versus 
a sulfonylurea (SU) or a dipeptidyl-peptidase-IV (DPP-4) inhibitor, when added to 
metformin, in Type 2 diabetes mellitus (T2DM) patients inadequately controlled on 
metformin in Greece. Methods: The published and validated CARDIFF diabetes 
model, a lifetime micro-simulation model, was adapted to the Greek health care 
setting to determine the incidence of micro- and macro-vascular complications 
and diabetes-specific and all-cause mortality. Clinical inputs were derived from a 
52-week randomized clinical trial and a network meta-analysis comparing dapa-
gliflozin with SU and DPP-4 inhibitor, respectively, in combination with metformin. 
Local unit costs and utility data were retrieved from literature and assigned to model 
parameters to calculate total quality-adjusted life years (QALYs) and total costs as 
well as incremental cost-effectiveness ratios (ICERs).The analysis was conducted 
from the perspective of a third-party payer in Greece. Uncertainty surrounding 
important model parameters was explored with probabilistic sensitivity analysis 
(PSA). Results: Over a patient’s lifetime, dapagliflozin was associated with 0.488 
(95% CI: 0.477-0.5) and 0.042 (95% CI: 0.03-0.054) incremental QALYs compared 
with SU and DPP-4 inhibitor, respectively, at additional costs of € 5,149 (95% CI: 
€ 5,026-€ 5,272) and € 755 (95% CI: € 636-€ 874), respectively. These findings were mainly 
driven by the beneficial effect of dapagliflozin on weight, and its higher drug acqui-
sition costs. The corresponding ICERs were € 10,545 and € 17,871 per QALY gained 
versus the treatment with SU and DPP-4, respectively. At the defined willingness-
to-pay threshold of € 34,000 per QALY gained, PSA results showed that treatment 
with dapagliflozin was estimated to have a 99% and 57.5% probability of being cost-
effective relative to the SU and DPP-4 treatments. ConClusions: Dapagliflozin in 
combination with metformin was shown to be a cost-effective treatment alterna-
tive for patients with T2DM whose metformin regimen does not provide sufficient 
glycemic control in the current Greek health care setting.
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objeCtives: Dulaglutide 1.5mg once weekly is a novel glucagon-like peptide 1 
receptor (GLP-1) agonist, for the treatment of type 2 diabetes mellitus (T2DM). 
The objective of this analysis was to estimate the cost-effectiveness of dulaglu-
tide versus liraglutide 1.8mg and liraglutide 1.2mg for the treatment of T2DM in 
Sweden. Methods: The IMS CORE Diabetes Model (CDM), a validated simula-
tion model, was used to estimate expected costs and outcomes. The compara-
tors investigated were liraglutide 1.8mg and liraglutide 1.2mg. In accordance 
with Swedish guidelines the analysis was conducted using a societal perspective 
including Swedish-specific direct and indirect costs over a lifetime time horizon. 
Comparative safety and efficacy data were derived from direct comparison of 
dulaglutide 1.5mg versus liraglutide 1.8mg from the AWARD-6 trial and from a 
network meta-analysis for the comparison of dulaglutide 1.5mg versus liraglutide 
1.2mg. One-way and probabilistic sensitivity analyses were conducted to explore 
the sensitivity of the model to plausible variations in key parameters and over-
all uncertainty. Results: Under base case assumptions, dulaglutide 1.5mg was 
found to be less costly and more effective versus liraglutide 1.8mg (total costs 
1,032,258 SEK vs 1,045,927 SEK; total QALYS 8.062 vs 8.033 for dulaglutide 1.5mg 
and liraglutide 1.8mg, respectively) and liraglutide 1.2mg (total costs 1,048,832 SEK 
vs 1,051,224 SEK; total QALYs 8.016 vs 7.974 for dulaglutide 1.5mg and liraglutide 
1.2mg, respectively). One-way sensitivity analyses demonstrated that dulaglutide 
1.5mg remained dominant versus liraglutide 1.8mg given plausible variations in 
key input parameters. Results of the probabilistic sensitivity analysis were con-
sistent with base case results. ConClusions: In the base case, the model found 
that dulaglutide 1.5mg was more effective and less costly than liraglutide 1.8mg 
and liraglutide 1.2mg for the treatment of T2DM in Swedish setting. Findings were 
robust to plausible variations in inputs. The introduction of dulaglutide 1.5mg may 
result in societal cost savings.
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objeCtives: Dapagliflozin, a sodium-glucose-transporter-protein-2 (SGLT2) inhibi-
tor, can serve as a treatment for type 2 diabetes mellitus (T2DM) in patients inad-
equately controlled on metformin mono-therapy. The relative health benefits and 
costs of dapagliflozin compared to a dipeptidyl-peptidase-4 inhibitor (DPP4), added 
to metformin, were assessed through a cost-effectiveness analysis (CEA) from a 
Turkish payer perspective. Methods: For the current CEA, a micro-simulation 
disease model (CARDIFF) was used. Clinical inputs were derived from a system-
atic review and network meta-analysis, along with a long-term follow-up study 
for dapagliflozin. In addition, Turkish specific cost data were collected and applied. 
The model predicted micro-and macro-vascular complications based on the UKPDS 
equations. Total Quality-Adjusted-Life-Years (QALYs) and costs were calculated over 
a lifetime horizon. Deterministic, probabilistic sensitivity analyses and elaborate 
scenario analyses were performed. Results: Compared to DPP4, dapagliflozin 
was associated with an incremental benefit of 0.590 QALYs (95% CI: 0.038; 1.232) 
and cost savings of TRY 494 (95% CI: TRY-1,727; TRY 889). Results were sensitive to 
